Table 1.
Characteristics and bivariate analysis by usage for PTSD categories for responses to a survey associated with the prescription of atypical antipsychotics
| Total | PTSD only | PTSD plus other diagnoses | No PTSD | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n = 2613 | n = 339 (13.0%) | n = 236 (9.0%) | n = 2038 (78.0%) | |||||||
| Variable | n | (%) | n | (%) | n | (%) | n | (%) | χ2 | p-value |
| Race/ethnicitya | ||||||||||
| White | 1991 | (81.9) | 263 | (85.4) | 180 | (81.4) | 1548 | (81.4) | 4.27 | 0.3704 |
| Black | 427 | (17.6) | 43 | (14.0) | 39 | (17.6) | 345 | (18.1) | ||
| Other | 12 | (0.5) | 2 | (0.7) | 2 | (0.9) | 8 | (0.4) | ||
| Medication | 74.68 | <0.0001 | ||||||||
| Aripiprazole | 390 | (14.9) | 31 | (9.1) | 54 | (22.9) | 305 | (15.0) | ||
| Olanzapine | 409 | (15.7) | 33 | (9.7) | 24 | (10.2) | 352 | (17.3) | ||
| Quetiapine | 1216 | (46.5) | 159 | (46.9) | 102 | (43.2) | 955 | (46.9) | ||
| Ziprazidone | 129 | (4.9) | 23 | (6.8) | 17 | (7.2) | 89 | (4.4) | ||
| LAI Risperidone | 34 | (1.3) | 0 | – | 1 | (0.4) | 33 | (1.6) | ||
| Risperidone Oral | 435 | (16.6) | 93 | (27.4) | 38 | (16.1) | 304 | (14.9) | ||
| Prescription Typeb | 15.79 | 0.0033 | ||||||||
| Change | 624 | (24.3) | 67 | (20.1) | 59 | (25.2) | 498 | (24.9) | ||
| Additional | 489 | (19.1) | 45 | (13.5) | 47 | (20.1) | 397 | (19.9) | ||
| New Prescription | 1452 | (56.6) | 222 | (66.5) | 128 | (54.7) | 1102 | (55.2) | ||
| Comorbid Medical Disorder | ||||||||||
| Movement Disorderc | 241 | (9.2) | 6 | (1.8) | 11 | (4.7) | 224 | (11.0) | 35.86 | <0.0001 |
| Obesity | 563 | (21.5) | 55 | (16.2) | 69 | (29.2) | 439 | (21.5) | 13.94 | 0.0009 |
| Diabetes Mellitus | 406 | (15.5) | 42 | (12.4) | 42 | (17.8) | 322 | (15.8) | 3.59 | 0.1666 |
| Hyperlipidemia | 786 | (30.1) | 113 | (33.3) | 83 | (35.2) | 590 | (28.9) | 5.85 | 0.5370 |
| Hypertension | 923 | (35.3) | 104 | (30.7) | 91 | (38.6) | 728 | (35.7) | 4.42 | 0.1095 |
| CAD | 295 | (11.3) | 32 | (9.4) | 28 | (11.9) | 235 | (11.5) | 1.36 | 0.5079 |
PTSD, post-traumatic stress disorder; LIA, long acting injectable; CAD, coronary artery disease.
a183 observations missing in the race/ethnicity category.
b48 observations missing in the prescription type category.
cMovement disorder includes tardive dyskinesia, extra-pyramidal symptoms, and akithesia.